Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma

NCT01533207 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT01533207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01533207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 3
Overall status
Terminated
Start date
June 4, 2012
Completion date
February 9, 2019
Enrollment
38 (actual)
Sites
623

Conditions

As the registry lists them; a condition with its own page is linked.

stage i uterine sarcoma ajcc v7, uterine corpus leiomyosarcoma